Application of Oil-in-Water Cannabidiol Emulsion for the Treatment of Rheumatoid Arthritis

Result code in IS VaVaI

<a href="https://www.isvavai.cz/riv?ss=detail&h=RIV%2F60461373%3A22340%2F24%3A43930924" target="_blank" >RIV/60461373:22340/24:43930924 - isvavai.cz</a>

Alternative codes found

RIV/00216208:11110/24:10450179 RIV/00216208:11310/24:10450179 RIV/00064203:_____/24:10450179 RIV/00064165:_____/24:10450179

Result on the web

<a href="https://www.liebertpub.com/doi/10.1089/can.2022.0176" target="_blank" >https://www.liebertpub.com/doi/10.1089/can.2022.0176</a>

DOI - Digital Object Identifier

<a href="http://dx.doi.org/10.1089/can.2022.0176" target="_blank" >10.1089/can.2022.0176</a>

Result language

angličtina

Original language name

Application of Oil-in-Water Cannabidiol Emulsion for the Treatment of Rheumatoid Arthritis

Original language description

Introduction: Rheumatoid arthritis (RA) is a chronic autoimmune disease with unknown cause. It mainly affects joints and, without proper treatment, negatively impacts their movement, causes painful deformities, and reduces the patients’ quality of life. Current treatment options consist of various types of disease-modifying antirheumatic drugs (DMARDs), however 20–30% of patients are partially resistant to them. Therefore, development of new drugs is necessary. Possible option are compounds exhibiting their action via endocannabinoid system, which plays an important role in pain and inflammation modulation. One such compound – cannabidiol (CBD) has already been shown to attenuate synovitis in animal model of RA in in vivo studies. However, it has low bioavailability due to its low water solubility and lipophilicity. This issue can be addressed by preparation of a lipid containing formulation targeting lymphatic system, another route of absorption in the body. Materials and Methods: CBD-containing emulsion was prepared by high-shear homogenization and its droplet size distribution was analysed by optical microscopy. The relative oral bioavailability compared to oil solution as well as total availability of CBD were assessed in a cross-over study in rats and absorption of CBD via lymphatic system was observed. The effect of CBD on the animal model of RA was determined. Results: Compared to oil solution, the emulsion exhibited higher absolute oral bioavailability. Significant lymphatic transport of CBD was observed in all formulations and the concentrations in lymph were calculated. The therapeutic effect of CBD on RA was confirmed as an improvement in clinical symptoms as well as morphological signs of disease activity were observed during the study. Conclusion: In this work, we prepared a simple stable emulsion formulation, determined the pharmacokinetic parameters of CBD and calculated its absolute bioavailability in rats. Moreover, we successfully tested the pharmaceutical application of such a formulation and demonstrated the positive effect of CBD in an animal model of RA. © Mary Ann Liebert, Inc.

Czech name

—

Czech description

—

Type

J_imp - Article in a specialist periodical, which is included in the Web of Science database

CEP classification

—

OECD FORD branch

20401 - Chemical engineering (plants, products)

Project

<a href="/en/project/NU22-08-00346" target="_blank" >NU22-08-00346: Combination of new cannabinoids and advanced formulation methods for treatment of rheumatoid arthritis</a><br>

Continuities

P - Projekt vyzkumu a vyvoje financovany z verejnych zdroju (s odkazem do CEP)

Publication year

2024

Confidentiality

S - Úplné a pravdivé údaje o projektu nepodléhají ochraně podle zvláštních právních předpisů

Name of the periodical

Cannabis and Cannabinoid Research

ISSN

2578-5125

e-ISSN

2378-8763

Volume of the periodical

9

Issue of the periodical within the volume

1

Country of publishing house

US - UNITED STATES

Number of pages

13

Pages from-to

147-159

UT code for WoS article

000880799700001

EID of the result in the Scopus database

2-s2.0-85185595247